|
Jul 31
|
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
|
|
Jul 30
|
Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue Estimates
|
|
Jul 30
|
Sage Therapeutics Announces Second Quarter 2025 Financial Results
|
|
Jul 28
|
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
|
|
Jul 25
|
ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression
|
|
Jul 1
|
Sector Update: Health Care Stocks Rise in Late Afternoon Trading
|
|
Jul 1
|
Sector Update: Health Care Stocks Advance Tuesday Afternoon
|
|
Jul 1
|
What Makes Sage Therapeutics (SAGE) a New Buy Stock
|
|
Jun 18
|
H.C. Wainwright sees potential competition for Sage from Biogen
|
|
Jun 17
|
SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal
|
|
Jun 17
|
Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock?
|
|
Jun 17
|
Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus
|
|
Jun 16
|
Supernus Pharmaceuticals Snaps Up Beleaguered Sage Therapeutics
|
|
Jun 16
|
Sage Therapeutics Stock Soars 36% After Sale to Supernus Pharmaceuticals. What We Know.
|
|
Jun 16
|
Supernus makes depression drug play with $795m Sage buyout
|
|
Jun 16
|
Sector Update: Health Care Stocks Flat to Higher Premarket Monday
|
|
Jun 16
|
Sage, following Setbacks, to sell to Supernus for $561M
|
|
Jun 16
|
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio
|
|
May 29
|
Why Is Sage Therapeutics (SAGE) Down 11.1% Since Last Earnings Report?
|
|
Apr 24
|
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for
|